Mahajan Therapeutics Wheelersburg

Mahajan Therapeutics Wheelersburg is a SAMHSA-registered addiction-treatment facility in Wheelersburg, OH. The facility offers a continuum of care across multiple levels — Outpatient, MAT, Dual Dx — which means it can, in principle, hold a patient across the arc of a typical treatment episode. This page frames the questions that matter most when evaluating a specific program — the ones that separate useful candidates from marginal ones.

Care levels at Mahajan Therapeutics Wheelersburg

On care levels: The facility offers a continuum of care across multiple levels — Outpatient, MAT, Dual Dx — which means it can, in principle, hold a patient across the arc of a typical treatment episode. The practical question is whether it is genuinely strong at each level, or whether one level is the core business and the others are secondary. The critical pre-admission step is an independent clinical assessment that establishes ASAM 4e level-of-care recommendation. Admission at a facility whose offered level does not match the clinical assessment produces most misaligned-placement outcomes.

Insurance and payment

Mahajan Therapeutics Wheelersburg accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. Before admission, request a written Verification of Benefits from the facility's utilization-review team. Verbal VOB is where most post-admission cost-sharing disputes originate. Written documentation settles them.

Specialty programming

The facility's documented specialty programming includes: Young adults, Seniors or older adults, Veterans. Specialty designations benefit from specific follow-up: programming hours per week, credentialed staff profile, integrated assessment protocols. Dual-diagnosis as a marketing category differs from operational specialty infrastructure.

Before you call

Three pre-admission questions for Mahajan Therapeutics Wheelersburg: (1) at what ASAM 4e level are you admitting me, and what is the clinical rationale; (2) can you provide written Verification of Benefits for my specific plan; (3) what is your MAT policy for opioid use disorder — specifically, do you continue buprenorphine or methadone during residential programming. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.